Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy

Although multiple active systemic treatments are now available for patients with metastatic kidney cancer, the tools to clearly identify patients who appear to benefit from cytoreductive surgery remain poorly defined or validated. To improve the level of evidence for future surgical research in metastatic renal cell cancer, it is imperative that specific tools be developed for advanced risk stratification in the context of evaluating the...